UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 90549

SCHEDULE 14A

(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]

Check the appropriate box:

[ ] Preliminary Proxy Statement
[ ] Confidential, For Use of the Commission Only (as permitted by Rule 14a–6(e)(2))
[ ] Definitive Proxy Statement
[X] Definitive Additional Materials
[ ] Soliciting Material under Rule 14a-12

ADVAXIS, INC.
(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.

[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transactions applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction.

(5) Total fee paid:

[ ] Fee paid previously with preliminary materials:

[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount previously paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

ADVAXIS
IMMUNOTHERAPIES

To My Fellow Stockholders,

In the nine months since I was appointed CEO of Advaxis, my colleagues and I have worked diligently to redefine the company and develop a product pipeline that prioritizes the opportunities presented by our proprietary *Lm* platform. The result is an organization with: a diversified portfolio of late- and early-stage clinical trials across drug constructs and cancer types; a significantly reduced cash burn that is consistent with a company of our size; and an anticipated series of potentially validating milestones through multiple data readouts and other events over the next 24 months.

We strongly believe our *Lm* construct differentiates Advaxis from others in the immunotherapy space through its unique ability to mimic a natural infection and redirect an immune response against the cancer cells. Our vector is designed to provide enhanced antigen presentation that activates multiple pathways and alerts and trains the immune system, thereby mobilizing and generating a cancer-specific T cell response to attack the tumor and reduce tumor-protective cells that shield the tumor from the immune system.

In many ways, our AXAL (axalimogene filolisbac) program is the foundational element of our science. It provides validation for our platform as more than 470 patients have been treated with our *Lm* product candidates in multiple clinical trials, the vast majority of which have been with AXAL in cervical cancer. As a single antigen construct, it has helped to drive our scientific curiosity as we have expanded to multiple antigen constructs with our ADXS-NEO and ADXS-HOT programs, and it has provided us with meaningful clinical experience that has demonstrated a manageable safety profile in patients studied.

On another front, we continue to follow patients in our Phase 1/2 trial with ADXS-PSA in combination with KEYTRUDA®, as part of our ongoing collaboration with Merck. Here again, we have focused on some of the most difficult-to-treat patients, as our focus is on metastatic, castration-resistant prostate cancer. Intriguing early data from seven of the 37 patients in this study presented this past June at ASCO demonstrated an improvement in survival in subjects with PSA declines from baseline of 50% or greater. Treatment-related adverse events were mostly mild or moderate constitutional symptoms such as fever, chills, rigors, hypotension, nausea and fatigue consistent with immune activation and manageable with standard care.

The second half of 2018 marked our entry into the clinic for the first of what we plan to be several neoantigen-directed drug candidates. ADXS-NEO are drug constructs that express personalized tumor antigens and ADXS-HOT are drug constructs that express public, or shared, antigens. While early stage, these programs present a very exciting opportunity for us. We, along with others in the scientific community, believe that neoantigens have the potential to change the treatment paradigm in many types of cancer. In December 2018, we announced that as of February 8, 2019 we will regain worldwide rights for the development and commercialization of our ADXS-NEO program, an investigational personalized immunotherapy previously partnered with Amgen. ADXS-NEO is currently in a Phase 1 dose-escalation study in subjects with various solid tumors and we anticipate the availability of safety, tolerability and immune correlative data in the first half of 2019.

For Advaxis, targeting multiple neoantigens is a natural extension of our established technology, and our constructs can target more than 30 neoantigens in a single therapy. Personalized vaccines in the neoantigen space are emerging as a critical component in oncology, and we believe we are at the forefront of this advance. During the third quarter of 2018 we received FDA allowance of our Investigational New Drug (IND) application for ADXS-503 for the treatment of non-small cell lung cancer (NSCLC). We expect that ADXS-503 will begin enrolling patients in early 2019 and anticipate having safety, tolerability and immune correlative data in the first half of 2019. Of additional note, both ADXS-NEO and ADXS-HOT are tumor agnostic, meaning there is potential for broad applicability in numerous solid tumor types. The proof-of-concept trials for ADXS-NEO include multiple cancer types, and we plan to enter clinical trials with drug candidates from our ADXS-HOT program in 2020 and beyond for prostate and bladder cancers, among others.

As a company, we are devoted to helping people suffering from cancer and their loved ones. As a management team, we are focused on making that happen as efficiently, cost effectively and as rapidly as possible, and in a manner that is consistent with creating value for our stockholders.

I thank you for your continued support and look forward to keeping you apprised of our progress.

Sincerely,

Kenneth A. Berlin
President and Chief Executive Officer
January 10, 2019

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.